Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...

A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

The SAPIEN M3 system received CE Mark in April 2025, making it the world’s first approved transfemoral transcatheter mitral ...

The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making ...

Severe valvular heart disease was not uncommon among patients with cancer, and intervention to manage the valvular disease ...

At age 51, I was diagnosed with severe rheumatic mitral stenosis. After a second round of tests, treatment was changed from open-heart surgery to balloon valvuloplasty. What can I do to help the ...

The mitral valve controls the flow of blood from the heart’s left atrium down to the left ventricle, where it is pumped out to the body. When part of the valve doesn’t close properly, it’s called ...

Mitral regurgitation (MR) and tricuspid regurgitation (TR) are two conditions involving backward leakage of blood through a heart valve when a ventricle contracts. People may experience either or both ...

Valvular atrial fibrillation (A-fib) involves a condition that leads to an irregular or abnormal heart rhythm. This can increase a person’s risk of cardiovascular complications, such as stroke.

At age 51, I was diagnosed with severe rheumatic mitral stenosis. After a second round of tests, treatment was changed from open-heart surgery to balloon valvuloplasty. What can I do to help the ...